TrialJectory, an AI-powered technology platform that matches cancer patients with personalized advanced treatment options, announced the availability of PRA Health Sciences' Health Harmony COVID-19 Monitoring Program for its global community of oncology patients. Access to this free program through the Health Harmony mobile app allows patients to monitor and report COVID-related symptoms from the comfort of their own homes to their healthcare providers.
The COVID-19 pandemic has had a devastating impact on cancer patients' daily lives. Aside from being one of the highest-risk populations due to patients' already compromised immune systems, cancer patients are also experiencing overburdened healthcare systems, resulting in the delay or cancellation of oncology treatment plans and required testing. As the U.S. begins a phased reopening, cancer patients must be even more vigilant about monitoring and preventing exposure to the virus.
Since March, thousands of users have downloaded the Health Harmony app and enrolled in the COVID-19 Monitoring Program through their employer, providers and healthcare networks. As part of the program, users can track their own COVID-19 symptoms and educate themselves about the disease. The COVID-19 Monitoring Program offers three levels of support to TrialJectory members, based on their personal situation:
Access to symptom monitoring and trained healthcare workers who are available to answer COVID questions will be critical during this time when disease transmission is still high, and a vaccine is not yet available. TrialJectory's partnership with PRA further highlights both companies' ongoing commitment to empowering cancer patients to take ownership of their personal healthcare journey.
"The Health Harmony COVID-19 program and its ability to track patient symptoms is a real-life example of how telehealth and mobile monitoring are quickly becoming the new standard of care in today's pandemic environment," said Kent Thoelke, Executive Vice President and Chief Scientific Officer, PRA Health Sciences. "The collaboration between our team at Care Innovations and TrialJectory brings that same technology directly into the hands of cancer patients across the U.S. and delivers greater healthcare access to people who need it the most."
"Since the outbreak, we have seen a significant increase in patient conversations within our community about how to prevent patients from contracting and spreading COVID-19," added Tzvia Bader, CEO and co-founder, TrialJectory. "It's vital-and even lifesaving-that cancer patients learn as much as they can about the virus, understand prevention techniques and quickly get their questions answered by qualified healthcare professionals who are dedicated specifically to this effort. Giving this tool to cancer patients brings us one step closer to making this a reality, allowing patients to remain fully informed, healthy and safe until the pandemic passes for good."
Cancer patients and their families need to remain vigilant when monitoring for the symptoms of COVID-19. With this disease continuing to spread at a high-rate of speed in the United States, the Health Harmony mobile app offers real-time access to biometric monitoring, educational materials and trained healthcare professionals – right at the patients' fingertips.
"Monitoring for Coronavirus symptoms using the app has given me back a sense of control that was completely lost as someone living with the risk of cancer recurrence during this pandemic," said Alin Wagner-Lahmy, a breast cancer survivor and mother of two. "Having one source of information that I can count on to be the most accurate, a way to track my health from day to day, and the ability to speak directly to a real person, has really helped to calm my anxiety."
To learn more, visit: https://www.trialjectory.com/covid-19-monitoring/
Zenocutuzumab Shows Durable Efficacy in NRG1 Fusion-Positive Cancers in Phase II eNRGy Trial
February 13th 2025The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 fusion–positive cancers, particularly non-small cell lung cancer and pancreatic cancer.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
SCOPE Summit 2025: Enhancing the Patient Experience Through Site Centricity
February 12th 2025In an interview with ACT senior editor Andy Studna at SCOPE Summit, Ashley Davidson, vice president, product lead - sponsor tech strategy, Advarra, highlights the need for more site-centric approaches in study startup.